MedTrace Logo

Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer

NCT06347198 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-04-04

No results posted yet for this study

Summary

This is a single-center exploratory clinical study to explore the efficacy and safety of Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer.

Conditions

Interventions

DRUG

Fruquintinib

Fruquintinib: 4 mg/d, qd po, administered continuously for 2 weeks, discontinued for 1 week;

DRUG

Sintilimab

Sintilimab: 200 mg, i.v.gtt.D1, administered every 3 weeks;

DRUG

Inulin

Inulin: 5g/d, qd po in the first week, 10g/d, bid po from the second week onwards.

Sponsors & Collaborators

  • Huazhong University of Science and Technology

    collaborator OTHER

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-10
Primary Completion
2024-12-01
Completion
2025-05-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06347198 on ClinicalTrials.gov